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Paediatric chemoprophylaxis for child 
contacts of patients with drug-resistant 
tuberculosis: Are current guidelines 
effective in preventing disease?
To the Editor: The World Health Organization (WHO) estimates that 
there were 480  000 new cases of multidrug-resistant tuberculosis 
(MDR-TB) in 2013.[1] Alarmingly, 40% of MDR-TB cases for which 
second-line drug susceptibility test results were reported originated in 
South Africa (SA).[1] This has important implications in vulnerable pop-
ulations, such as children, where infection with drug-resistant strains of 
TB are usually attributable to transmission rather than acquisition of 
resistance.[2] In high-burden settings, it is estimated that there are at least 
two child contacts who are either HIV-infected or younger than 5 years 
of age for every MDR-TB source case.[3,4] The growing spread of MDR-
TB, the protracted and toxic nature of current treatment regimens and 
the associated morbidity and mortality all emphasise the need for effec-
tive preventive therapy. There is limited evidence on optimal paediatric 
chemoprophylaxis to prevent disease in child contacts of MDR-TB 
cases, and the subject remains controversial. We have examined recent-
ly adapted paediatric chemoprophylactic guidelines and evaluated their 
effectiveness in the context of drug-resistant TB. We highlight a critical 
gap in research that is urgently needed to guide policy.
The 2013 South African Guidelines for the Management of Tuberculosis 
in Children make the following recommendations, following exclusion of 
TB disease: (i) isoniazid preventive therapy (IPT; 10 - 15 mg/kg/day for 6 
months) in all child contacts that are HIV infected or <5 years of age; (ii) 
rifampicin (15 mg/kg/day for 4 months) in isoniazid mono-resistant index 
cases; and (iii) high-dose isoniazid (15 - 20 mg/kg for 6 months) for neonates 
born to mothers with infectious drug-resistant TB.[5] While IPT significantly 
reduces the risk of drug-susceptible TB disease, and possibly TB strains with 
low-level isoniazid resistance, its applicability in the prevention of MDR-TB 
disease is questionable. Indeed, Kritski et al.[6] found that isoniazid had no 
protective effect in adult and child contacts of MDR-TB patients. In addition, 
Sneag et al.[7] described the failure of chemoprophylaxis with standard 
antituberculosis agents in five child contacts of MDR-TB patients.
There are no randomised chemoprophylaxis clinical trials for child 
contacts of MDR-TB patients. A prospective study in the Federal States 
of Micronesia found that of 110 adult and child MDR-TB contacts, 
administered a tailored (based on the susceptibility pattern of the source 
case) 12-month, multidrug prophylactic regimen, none developed TB 
disease.[8] Two studies conducted in SA report similar findings. Schaaf et al. [3] 
prospectively followed up 105 child contacts of adult MDR-TB patients for 
30 months. Only 5% (2/41) of children who received an individualised, 
multidrug prophylactic regimen developed TB disease compared with 
20% (13/64) of children who were monitored without preventive therapy. 
Most recently, Seddon et al.[9] demonstrated that a three-drug prophylactic 
regimen consisting of high-dose isoniazid, ofloxacin and ethambutol for 6 
months was both effective and well tolerated in child contacts of MDR-TB; 
only 3.2% of children (6/186) developed incident TB.
Although there is a growing number of observational studies suggesting 
that MDR-TB chemoprophylaxis may be beneficial in MDR-TB-exposed 
children, there is still a lack of international consensus on the management 
of child contacts of MDR-TB patients. The WHO does not advocate the 
use of second-line agents as chemoprophylaxis for contacts of MDR-TB 
patients.[5] Likewise, the UK National Institute for Health and Clinical 
Excellence recommends close follow-up rather than intervention.[4] In 
contrast, several US institutions support the use of a regimen containing 
two drugs to which the source case is susceptible.[4] Such discordance is 
largely attributable to the potential adverse effects associated with anti-
MDR-TB drugs. Both Bamrah et al.[8] and Seddon et al.[9] have reported 
good drug tolerability, however, with only 0 - 5.5% of patients experiencing 
adverse effects necessitating treatment interruption.
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The lifetime risk of progression to active TB disease is 5 - 15% in people 
with latent infection.[10] Given that this figure rises sharply to 50% in 
children younger than 12 months,[11] and that inadequate chemotherapy 
may result in significant morbidity, the management of children with latent 
TB (including MDR-TB) is fundamental to TB control. In the absence of 
a randomised clinical trial, observational studies strongly indicate that 
appropriate MDR-TB chemoprophylaxis should be considered when TB 
disease has been excluded, there is significant exposure to a close drug-
resistant TB contact and the risk of disease progression is high. More 
research is urgently required to conclusively guide policy.
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